Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Brimonidine UD in open-angle glaucoma and ocular hypertension
2015-001489-24Phase 3Terminated
- Sponsor
- Pharma Stulln
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of brimonidine in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Pharma Stulln. Primary endpoint: Reduction of intraocular pressure. Started Jul 2015; status: terminated.
02
Drugs
brimonidine
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2015-001489-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001489-24.